Previous 10 | Next 10 |
2023-08-06 09:00:00 ET Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime soon. Even so, individual healthcare companies must constantly innovate...
2023-08-03 12:23:03 ET Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Conference Call August 03, 2023, 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executiv...
2023-08-03 08:00:28 ET More on Regeneron Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check Regeneron cut to N...
2023-08-03 06:31:33 ET Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q2 Non-GAAP EPS of $10.24 beats by $0.34 . Revenue of $3.16B (+10.5% Y/Y) beats by $140M . "Regeneron delivered strong financial results in the second quarter of 2023 through incre...
2023-08-02 08:00:00 ET Summary Shares of Regeneron pulled back after the company received a complete response letter for Eylea. The CRL can result in a market arrival delay of 9 to 12 months for Eylea and creates a wider opening for Roche's Vabysmo. Continued erosion should be...
TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research. Each year, Regeneron...
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements At two years, 44% of patients met the criteria for ≥20-week dosing intervals, in...
2023-07-27 10:57:33 ET Summary Shares of Kiniksa Pharmaceuticals surged after the company reported strong Q2 results and raised the full-year net sales guidance for Arcalyst. The strong growth and improved outlook were driven by the recent sales force expansion. I see Arcalyst...
2023-07-26 23:18:28 ET Summary Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and ATTR have provided solid validation for Intellia's...
2023-07-26 15:04:29 ET The World Health Organization updated its Essential Medicines List on Wednesday without adding a class of weight loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists as a treatment for obesity. The list designed to guide state procurement deci...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...